Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma-Reference-Cited by-同舟云学术

Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma

Published:2022-07-01 Issue:7 Volume:8 Page:1035
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Wang Xinhua¹,Zhang Lei¹,Liu Xiangli¹,Li Xin¹,Li Ling¹,Fu Xiaorui¹,Sun Zhenchang¹,Wu Jingjing¹,Zhang Xudong¹,Yan Jiaqin¹,Chang Yu¹,Nan Feifei¹,Zhou Zhiyuan¹,Wu Xiaolong¹,Tian Li¹,Ma Minrui¹,Li Zhaoming¹,Yu Hui¹,Zhu Linan¹,Wang Yingjun¹,Shi Cunzhen¹,Feng Xiaoyan¹,Li Jiwei¹,Ding Mengjie¹,Zhang Jieming¹,Dong Meng¹,Xue Hongwei²,Wang Jinghua³,Zou Liqun⁴,Su Liping⁵,Wu Jianqiu⁶,Liu Lihong⁷,Bao Huizheng⁸,Zhang Liling⁹,Guo Yanzhen¹⁰,Guo Shuxia¹¹,Lu Yi¹²,Young Ken H.¹³,Li Wencai¹⁴,Zhang Mingzhi¹

Affiliation:

1. Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

2. Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China

3. Department of Oncology, Nanjing Jinling Hospital, Nanjing University School of Medicine, Nanjing, China

4. Department of Oncology, Sichuan University West China Hospital, Chengdu, China

5. Department of Hematology, Tumor Hospital of Shanxi Medical University, Taiyuan, China

6. Department of Oncology, Jiangsu Cancer Hospital, Nanjing, China

7. Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

8. Department of Lymphoma and Hematology, Jilin Cancer Hospital, Jilin, China

9. Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hefei, China

10. Department of Oncology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China

11. Department of Hematology, Zhengzhou People’s Hospital, Zhengzhou, China

12. Department of Oncology, Xinxiang Central Hospital, Xinxiang, China

13. Division of Hematopathology, Department of Pathology, Duke University Medical Center and Duke Cancer Institute, Durham, North Carolina

14. Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2793566/jamaoncology_wang_2022_oi_220021_1658255452.00215.pdf

Reference24 articles.

1. Clinical features and current optimal management of natural killer/T-cell lymphoma.;Makita;Hematol Oncol Clin North Am,2017

2. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma.;Li;J Clin Oncol,2006

3. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma.;Kwong;Ann Oncol,2018

4. NK/T Cell lymphoma: updates in therapy.;Suzuki;Curr Hematol Malig Rep,2018

5. Efficacy and tolerance of pegaspargase, gemcitabine and oxaliplatin with sandwiched radiotherapy in the treatment of newly-diagnosed extranodal nature killer (NK)/T cell lymphoma.;Jing;Leuk Res,2016

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LMP1 enhances aerobic glycolysis in natural killer/T cell lymphoma;Cell Death & Disease;2024-08-20

2. CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphoma;Cancer Letters;2024-08

3. Challenges in overcoming advanced-stage or relapsed refractory extranodal NK/T-cell lymphoma: meta-analysis of individual patient data;Frontiers in Oncology;2024-07-31

4. A novel prognostic index for extranodal natural killer/T-cell lymphoma in the era of pegaspargase/L-asparaginase;Future Oncology;2024-07-23

5. Surface temperature characteristics of patients with malignant lymphoma based on infrared thermal imaging technology;2024-07-03